Recordati first-half core profit rises 8.8% on rare diseases

• Rare diseases revenue surged 17.1% to €603.9 million, with Isturisa (Cushing's syndrome treatment) jumping 58% to €178.8 million
• The takeover offer was deemed 'fair' by a majority of the board, though four independent directors dissented from this view
• CEO Rob Koremans attributed growth to expanded physician adoption, increased patient demand, and improved commercial execution in rare diseases

Recordati H1 Results Summary

Financial Performance:

Italian pharmaceutical company Recordati reported an 8.8% increase in first-half core profit (EBITDA) to €540.2 million ($615.6 million) on July 28. Adjusted net income rose 6.7% to €349.9 million.

Key Growth Driver:

The rare diseases segment drove results, with revenue surging 17.1% to €603.9 million. Star performer Isturisa, a treatment for Cushing's syndrome, posted exceptional growth of 58% to €178.8 million. CEO Rob Koremans attributed this success to expanded physician adoption, increased patient demand, and improved commercial execution.

Strategic Context:

The results come amid a significant corporate development. A majority of Recordati's board has deemed a €10.7 billion cash takeover offer from private equity firm CVC Capital Partners and Belgian investment group Groupe Bruxelles Lambert as "fair." However, four independent directors dissented from this view, suggesting potential governance concerns around the valuation.

Forward Guidance:

The Milan-based company confirmed its full-year 2026 financial targets, indicating management confidence in sustained growth momentum.

Market Implications:

The strong rare diseases performance demonstrates Recordati's successful specialization strategy in high-value therapeutic areas. The pending takeover at €10.7 billion values the company's rare disease portfolio and pipeline attractively for the acquirers, though the independent directors' dissent may signal the offer undervalues future growth potential. Investors should monitor whether the acquisition proceeds or if competing bids emerge given the company's strong operational performance.